Document is current
Any future updates will be listed below
-
Authors
Afeyan, Alexander B. https://orcid.org/0000-0003-0525-7166
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Oliveira, Giacomo https://orcid.org/0000-0001-7435-5603
-
Funding
Funding for this research was provided by:
Dana-Farber/Harvard Cancer Center (CA101942)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA287975-01)
U.S. Department of Health & Human Services | National Institutes of Health (2U24CA224331-02)
- License Information
-
More Information
Article History
Received: 5 March 2024
Accepted: 6 August 2024
First Online: 8 November 2024
Competing interests
: G.O is consultant for Bicycle Therapeutics. C.J.W. is an equity holder of BioNtech, Inc.; is a member of the scientific advisory board of Adventris, Aethon Therapeutics, and Repertoire; and receives research funding from Pharmacyclics. A.B.A. declares no competing interests.
